Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04251416 · ClinicalTrials.gov registry record · Phase 2
A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
A Phase 2 study of Endometrial Carcinoma, sponsored by Yale University.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04251416: Active Phase 2 study of Endometrial Carcinoma, sponsored by Yale University.
NCT04251416 is a Phase 2 study of Endometrial Carcinoma that is active but no longer recruiting, run by Yale University. The registered enrollment target is 50 participants, below the 389-participant average among 27 other Endometrial Carcinoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04251416, a Phase 2 study of Endometrial Carcinoma, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with persistent or recurrent endometrial carcinoma.
Primary Outcome
Objective response rate (complete response and partial response rates) by RECIST1.1 criteria in patients with persistent or recurrent endometrial carcinoma (EC)
Conditions Studied
Interventions
- DRUG Sacituzumab Govitecan
Study Locations (1)
Connecticut
- Smilow Cancer Hospital at Yale New Haven - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2020-03-17 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
What the registry record for NCT04251416 still lists
NCT04251416 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 389-participant average among 27 other Endometrial Carcinoma trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Endometrial Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Sacituzumab Govitecan is the first listed.
NCT04251416 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT04251416 about?
NCT04251416 is a clinical study titled "A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma". This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with persistent or recurrent endometrial carcinoma.
What is the current status of trial NCT04251416?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2020-03-17. Estimated completion is 2027-02.
What conditions does trial NCT04251416 study?
This clinical trial studies the following conditions: Endometrial Carcinoma.
What interventions are being tested in trial NCT04251416?
The interventions under investigation include: Sacituzumab Govitecan (DRUG).
Who is sponsoring clinical trial NCT04251416?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04251416 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04251416's enrollment target sits among peer trials
50 19th of 27 higher than 9 of 27 other Endometrial Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RECRUITING · Phase 2
-
Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy
ACTIVE NOT RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Nivolumab in Selected Uterine Cancer Patients
COMPLETED · Phase 2
-
Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI